RxDoctor Payments Data

Rubina Husain, MD

Internal Medicine · Long Beach, CANPI 1720046717

Payments from drug & device makers

$402in general payments, 2019–2025

Across 20 payments — averaging $20.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$68
  • AstraZeneca$68
  • Lilly USA, LLC$49
  • Biohaven Pharmaceuticals, Inc.$47
  • Abbott$43
  • Novo Nordisk$24
  • plus $104 from 6 others

What the payments were for

  • Food & beverage$402100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$402 in reported general payments places this provider in the 60th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$54,859
Medicare patients
199
Services billed
627

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide182$205,874
EliquisApixaban69$69,334
JanuviaSitagliptin Phosphate42$60,655
JardianceEmpagliflozin31$31,251
XareltoRivaroxaban17$22,164
FarxigaDapagliflozin Propanediol13$16,046
MounjaroTirzepatide11$10,902
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$10,541
MyrbetriqMirabegron12$7,225
Rosuvastatin Calcium454$7,209
Wixela InhubFluticasone Propion/Salmeterol30$6,691
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,598
Fluticasone-SalmeterolFluticasone Propion/Salmeterol40$5,134
Losartan Potassium447$4,902
Albuterol Sulfate HfaAlbuterol Sulfate145$4,714

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$24$205,874182 claims
PfizerEliquis$19$69,33469 claims
Johnson & JohnsonXarelto$12$22,16417 claims
AstraZenecaFarxiga$68$16,04613 claims
Lilly USA, LLCMounjaro$49$10,90211 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Long Beach

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →